Last reviewed · How we verify
SODIUM ASCORBATE
Sodium Ascorbate is a marketed drug with a key composition patent expiring in 2028. The drug's primary strength lies in its established market presence and long-standing use. The primary risk is the potential increase in competition following the patent expiry in 2028.
At a glance
| Generic name | SODIUM ASCORBATE |
|---|---|
| Drug class | Vitamin D [EPC] |
| Modality | Small molecule |
| Phase | FDA-approved |
| First approval | 2006 |
Approved indications
Common side effects
Key clinical trials
- Toddler Biomarker of Nutrition Study (NA)
- The Physiological Responses and Adaptation of Brown Adipose Tissue to Chronic Treatment With Beta3-Adrenergic Receptor Agonists (PHASE1)
- Regenerative Potentials of Mature Mandibular Molars With Symptomatic Irreversible Pulpitis Enhanced With Different Scaffolds (NA)
- Urine and Ultrasound Screening for Kidney Disease in Children (NA)
- The Body's Affect on Vitamin C (PHASE1)
- 177Lu-DOTA-EB-TATE in Adult Patients With Metastatic, Radioactive Iodine Non-Responsive Oncocytic (Hurthle-Cell) Thyroid Cancer (PHASE1, PHASE2)
- A Phase 2 Study Adding Ascorbate to Chemotherapy and Radiation Therapy for NSCLC (PHASE2)
- Vitamin C for Acute Kidney Injury in ACLF With Septic Shock: A Randomized Controlled Trial (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SODIUM ASCORBATE CI brief — competitive landscape report
- SODIUM ASCORBATE updates RSS · CI watch RSS